Multi-center, prospective study is performed to investigate the efficacy of new short-course regimen for retreatment pulmonary tuberculosis patients.
To obtain optimized short-course regimen, decrease treatment cost and improve success rate.

开始日期2013-06-01

申办/合作机构

上海市肺科医院

[+3]

100 项与帕司烟肼相关的临床结果

登录后查看更多信息

100 项与帕司烟肼相关的转化医学

登录后查看更多信息

100 项与帕司烟肼相关的专利（医药）

登录后查看更多信息

233

项与帕司烟肼相关的文献（医药）

2024-05-02·Inflammatory Bowel Diseases

Controlled Hookworm Infection for Medication-free Maintenance in Patients with Ulcerative Colitis: A Pilot, Double-blind, Randomized Control Trial

Article

作者: Maclean, Kate ; Inns, Stephen ; Camberis, Mali ; Yumnam, Bibek ; Mules, Thomas C ; Tang, Jeffry ; Noble, Sophia-Louise ; Vacca, Francesco ; Gasser, Olivier ; Cait, Alissa ; Stanley, James ; Le Gros, Graham ; Lavender, Brittany ; O'Sullivan, David ; Te Kawa, Tama

AbstractBackgroundHuman hookworm has been proposed as a treatment for ulcerative colitis (UC). This pilot study assessed the feasibility of a full-scale randomized control trial examining hookworm to maintain clinical remission in patients with UC.MethodsTwenty patients with UC in disease remission (Simple Clinical Colitis Activity Index [SCCAI] ≤4 and fecal calprotectin (fCal) <100 ug/g) and only on 5-aminosalicylate received 30 hookworm larvae or placebo. Participants stopped 5-aminosalicylate after 12 weeks. Participants were monitored for up to 52 weeks and exited the study if they had a UC flare (SCCAI ≥5 and fCal ≥200 µg/g). The primary outcome was difference in rates of clinical remission at week 52. Differences were assessed for quality of life (QoL) and feasibility aspects including recruitment, safety, effectiveness of blinding, and viability of the hookworm infection.ResultsAt 52 weeks, 4 of 10 (40%) participants in the hookworm group and 5 of 10 (50%) participants in the placebo group had maintained clinical remission (odds ratio, 0.67; 95% CI, 0.11-3.92). Median time to flare in the hookworm group was 231 days (interquartile range [IQR], 98-365) and 259 days for placebo (IQR, 132-365). Blinding was quite successful in the placebo group (Bang’s blinding index 0.22; 95% CI, −0.21 to 1) but less successful in the hookworm group (0.70; 95% CI, 0.37-1.0). Almost all participants in the hookworm group had detectable eggs in their faeces (90%; 95% CI, 0.60-0.98), and all participants in this group developed eosinophilia (peak eosinophilia 4.35 × 10^9/L; IQR, 2.80-6.68). Adverse events experienced were generally mild, and there was no significant difference in QoL.ConclusionsA full-scale randomized control trial examining hookworm therapy as a maintenance treatment in patients with UC appears feasible.

2024-05-01·JPGN Reports

Rescue therapy with upadacitinib in medically refractory pediatric ulcerative colitis

作者: Miller, Maria ; Pasternak, Brad ; Patel, Ashish S

AbstractApproved options for advanced therapy in pediatric inflammatory bowel disease (IBD) are limited. Although Janus kinase (JAK) inhibitors are approved in adult IBD, their benefit in pediatric populations is not yet delineated. We present a 13‐year‐old female patient with ulcerative colitis (UC) refractory to numerous therapies and courses of prednisone that ultimately responded to a JAK inhibitor. Initial treatment consisted of 5‐aminosalicylate and azathioprine. This was changed to adalimumab due to persistent symptoms. Repeat colonoscopy revealed pancolitis, thus she was transitioned to vedolizumab. She was hospitalized twice for uncontrolled symptoms on vedolizumab and subsequent scope showed continued pancolitis. As a result, she transitioned to ustekinumab without symptomatic relief after adjusting to monthly dosing. The family declined colectomy, opting to exhaust all medical therapies. Upadacitinib was started and her symptoms resolved within 1 week, and she remains in steroid‐free remission. This case illustrates the possible role of JAK inhibitors in extensively refractory pediatric UC patients before colectomy.

2024-04-22·Current Pharmaceutical Biotechnology

Emerging Natural Therapies for the Treatment of Inflammatory Bowel Disease

Article

作者: Pandey, Manju ; Ved, Akash ; Joshi, Monika ; Shankar, Ravi

Abstract:The term "inflammatory bowel disease," which includes Crohn's disease (CD) and ulcerative colitis (UC), refers to a chronic inflammatory condition of the digestive system. There are many different treatment options, such as corticosteroids, biologics, 5-aminosalicylate, and immune-suppressants, but none of them can maintain the disease remission for a longer period, which is the ultimate goal of treatment. Furthermore, they have numerous serious side effects like nephrotoxicity, infertility, congestive heart failure, myopathy, etc. So, in order to treat these conditions, researchers are concentrating more on natural medicine that is less expensive and has fewer side effects. The current analysis includes a list of plants showing promising activity against IBD. These include Cannabis sativa, Aloe vera, Boswellia serrata, Withania somnifera, Curcuma longa, Triticum aestivum, and many others. These plants need to be further investigated in terms of preclinical and clinical studies to obtain the safety and efficacy data necessary for their commercialisation. Global regulatory norms will facilitate simple commercialisation. Also, more investigation is required to pinpoint the precise mechanism of action to confirm clinical success.

100 项与帕司烟肼相关的药物交易

登录后查看更多信息